Jiaye Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiaye Zhao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Guangmei Li
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, Hebei, China
1 shared publication - Liwenjing Xu
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, Hebei, China
1 shared publication - Qiyu Sun
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical College, Chengde, Hebei Province, China
1 shared publication - Tingyun Xue
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, Hebei, China
1 shared publication - Zhenrong Yan
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, Hebei, China
1 shared publication - Ziyang Xing
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, Hebei, China
1 shared publication
Latest Publications
- Open Access
- 1 March 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (9) , e37279
Insulin-like growth factor-1 in myocardial ischemia-reperfusion injury: A review
Myocardial ischemia-reperfusion injury (MIRI) is a severe damage inflicted on the ischemic myocardium when blood flow is restored, and it commonly occurs in a wide range of cardiovascular diseases. Presently, no effective clinical treatment exists for MIRI. Accumulating evidence indicates that insulin-like growth factor-1 (IGF-1) plays a role in the intricate chain of cardiovascular events, in addition to its well-recognized growth-promoting and metabolic effects. IGF-1, a member of the insulin family, exhibits a broad spectrum of protective effects against ischemia/reperfusion injury in various tissues, especially the myocardium. In particular, earlier research has demonstrated that IGF-1 reduces cellular oxidative stress, improves mitochondrial function, interacts with noncoding RNAs, and activates cardiac downstream protective genes and protective signaling channels. This review aimed to summarize the role of IGF-1 in MIRI and elucidate its related mechanisms of action. In addition, IGF-1-related interventions for MIRI, such as ischemic preconditioning and post-conditioning, were discussed. The purpose of this review was to provide evidence supporting the activation of IGF-1 in MIRI and advocate its use as a therapeutic target.
- 1 March 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (9) , e37279
Open AccessInsulin-like growth factor-1 in myocardial ischemia-reperfusion injury: A review
Myocardial ischemia-reperfusion injury (MIRI) is a severe damage inflicted on the ischemic myocardium when blood flow is restored, and it commonly occurs in a wide range of cardiovascular diseases. Presently, no effective clinical treatment exists for MIRI. Accumulating evidence indicates that insulin-like growth factor-1 (IGF-1) plays a role in the intricate chain of cardiovascular events, in addition to its well-recognized growth-promoting and metabolic effects. IGF-1, a member of the insulin family, exhibits a broad spectrum of protective effects against ischemia/reperfusion injury in various tissues, especially the myocardium. In particular, earlier research has demonstrated that IGF-1 reduces cellular oxidative stress, improves mitochondrial function, interacts with noncoding RNAs, and activates cardiac downstream protective genes and protective signaling channels. This review aimed to summarize the role of IGF-1 in MIRI and elucidate its related mechanisms of action. In addition, IGF-1-related interventions for MIRI, such as ischemic preconditioning and post-conditioning, were discussed. The purpose of this review was to provide evidence supporting the activation of IGF-1 in MIRI and advocate its use as a therapeutic target.